129 related articles for article (PubMed ID: 30981500)
1. PFKFB3/HIF-1α feedback loop modulates sorafenib resistance in hepatocellular carcinoma cells.
Long Q; Zou X; Song Y; Duan Z; Liu L
Biochem Biophys Res Commun; 2019 Jun; 513(3):642-650. PubMed ID: 30981500
[TBL] [Abstract][Full Text] [Related]
2. Long Noncoding RNA URB1-Antisense RNA 1 (AS1) Suppresses Sorafenib-Induced Ferroptosis in Hepatocellular Carcinoma by Driving Ferritin Phase Separation.
Gao Y; Tong M; Wong TL; Ng KY; Xie YN; Wang Z; Yu H; Loh JJ; Li M; Ma S
ACS Nano; 2023 Nov; 17(22):22240-22258. PubMed ID: 37966480
[TBL] [Abstract][Full Text] [Related]
3. VEGF/Nrp1/HIF-1α promotes proliferation of hepatocellular carcinoma through a positive feedback loop.
Wang YB; Zheng KW; Hu YY; Salameen H; Zhu ZY; Wu FF; Ding X
Med Oncol; 2023 Oct; 40(12):339. PubMed ID: 37875691
[TBL] [Abstract][Full Text] [Related]
4. Targeting the HIF-1α/Cav-1 Pathway with a Chicory Extract/Daidzein Combination Plays a Potential Role in Retarding Hepatocellular Carcinoma.
Zakaria S; Nawaya R; Abdel-Hamid NM; Eldomany RA; El-Shishtawy MM
Curr Cancer Drug Targets; 2021; 21(10):881-896. PubMed ID: 34382525
[TBL] [Abstract][Full Text] [Related]
5. NR0B1 augments sorafenib resistance in hepatocellular carcinoma through promoting autophagy and inhibiting apoptosis.
Tan XL; Wang Z; Liao S; Yi M; Tao D; Zhang X; Leng X; Shi J; Xie S; Yang Y; Liu YQ
Cancer Sci; 2024 Feb; 115(2):465-476. PubMed ID: 37991109
[TBL] [Abstract][Full Text] [Related]
6. Oncofetal HLF transactivates c-Jun to promote hepatocellular carcinoma development and sorafenib resistance.
Xiang DM; Sun W; Zhou T; Zhang C; Cheng Z; Li SC; Jiang W; Wang R; Fu G; Cui X; Hou G; Jin GZ; Li H; Hou C; Liu H; Wang H; Ding J
Gut; 2019 Oct; 68(10):1858-1871. PubMed ID: 31118247
[TBL] [Abstract][Full Text] [Related]
7. 2-Methoxyestradiol synergizes with Erlotinib to suppress hepatocellular carcinoma by disrupting the PLAGL2-EGFR-HIF-1/2α signaling loop.
Zheng S; Ni J; Li Y; Lu M; Yao Y; Guo H; Jiao M; Jin T; Zhang H; Yuan A; Wang Z; Yang Y; Chen Z; Wu H; Hu W
Pharmacol Res; 2021 Jul; 169():105685. PubMed ID: 34022398
[TBL] [Abstract][Full Text] [Related]
8. Mitophagy promotes sorafenib resistance through hypoxia-inducible ATAD3A dependent Axis.
Wu H; Wang T; Liu Y; Li X; Xu S; Wu C; Zou H; Cao M; Jin G; Lang J; Wang B; Liu B; Luo X; Xu C
J Exp Clin Cancer Res; 2020 Dec; 39(1):274. PubMed ID: 33280610
[TBL] [Abstract][Full Text] [Related]
9. Cancer-associated fibroblasts induce sorafenib resistance of hepatocellular carcinoma cells through CXCL12/FOLR1.
Zhao J; Lin E; Bai Z; Jia Y; Wang B; Dai Y; Zhuo W; Zeng G; Liu X; Cai C; Li P; Zou B; Li J
BMC Cancer; 2023 Dec; 23(1):1198. PubMed ID: 38057830
[TBL] [Abstract][Full Text] [Related]
10. Reversal of sorafenib resistance in hepatocellular carcinoma: epigenetically regulated disruption of 14-3-3η/hypoxia-inducible factor-1α.
Qiu Y; Shan W; Yang Y; Jin M; Dai Y; Yang H; Jiao R; Xia Y; Liu Q; Ju L; Huang G; Zhang J; Yang L; Li L; Li Y
Cell Death Discov; 2019; 5():120. PubMed ID: 31341646
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of PTPRE suppresses tumor progression and improves sorafenib response in hepatocellular carcinoma.
Dong R; Wang T; Dong W; Zhu H; Liu Q; Liang H; Chen X; Zhang B; Zhang X
Biomed Pharmacother; 2024 Apr; 173():116366. PubMed ID: 38458013
[TBL] [Abstract][Full Text] [Related]
12. Signaling metabolite succinylacetone activates HIF-1α and promotes angiogenesis in GSTZ1-deficient hepatocellular carcinoma.
Luo H; Wang Q; Yang F; Liu R; Gao Q; Cheng B; Lin X; Huang L; Chen C; Xiang J; Wang K; Qin B; Tang N
JCI Insight; 2023 Oct; 8(23):. PubMed ID: 37906252
[TBL] [Abstract][Full Text] [Related]
13. Impact of glucose metabolism on PD-L1 expression in sorafenib-resistant hepatocellular carcinoma cells.
Cho S; Kim W; Yoo D; Han Y; Hwang H; Kim S; Kim J; Park S; Park Y; Jo H; Pyun JC; Lee M
Sci Rep; 2024 Jan; 14(1):1751. PubMed ID: 38243049
[TBL] [Abstract][Full Text] [Related]
14. Aldehyde Dehydrogenase 2 (ALDH2): A novel sorafenib target in hepatocellular carcinoma unraveled by the proteome-wide cellular thermal shift assay.
Ferreira IC; Torrejón E; Abecasis B; Alexandre BM; Gomes RA; Verslype C; van Pelt J; Barbas A; Simão D; Bandeiras TM; Bortoluzzi A; Rebelo SP
SLAS Discov; 2024 Apr; 29(3):100154. PubMed ID: 38521503
[TBL] [Abstract][Full Text] [Related]
15. From synergy to resistance: Navigating the complex relationship between sorafenib and ferroptosis in hepatocellular carcinoma.
Wang Z; Zhou C; Zhang Y; Tian X; Wang H; Wu J; Jiang S
Biomed Pharmacother; 2024 Jan; 170():116074. PubMed ID: 38147732
[TBL] [Abstract][Full Text] [Related]
16. The efficacy of sorafenib against hepatocellular carcinoma is enhanced by 5-aza-mediated inhibition of ID1 promoter methylation.
Meng J; Li S; Niu ZQ; Bao ZQ; Niu LL
FEBS Open Bio; 2024 Jan; 14(1):127-137. PubMed ID: 37964494
[TBL] [Abstract][Full Text] [Related]
17. Burning down the house: Pyroptosis in the tumor microenvironment of hepatocellular carcinoma.
Cheng C; Hsu SK; Chen YC; Liu W; Shu ED; Chien CM; Chiu CC; Chang WT
Life Sci; 2024 Jun; 347():122627. PubMed ID: 38614301
[TBL] [Abstract][Full Text] [Related]
18. Glycolysis maintains AMPK activation in sorafenib-induced Warburg effect.
Guo S; Zhang C; Zeng H; Xia Y; Weng C; Deng Y; Wang L; Wang H
Mol Metab; 2023 Nov; 77():101796. PubMed ID: 37696356
[TBL] [Abstract][Full Text] [Related]
19. Hypoxia signaling in hepatocellular carcinoma: Challenges and therapeutic opportunities.
Sin SQ; Mohan CD; Goh RMW; You M; Nayak SC; Chen L; Sethi G; Rangappa KS; Wang L
Cancer Metastasis Rev; 2023 Sep; 42(3):741-764. PubMed ID: 36547748
[TBL] [Abstract][Full Text] [Related]
20. Mechanistic Insights about Sorafenib-, Valproic Acid- and Metformin-Induced Cell Death in Hepatocellular Carcinoma.
Franco-Juárez EX; González-Villasana V; Camacho-Moll ME; Rendón-Garlant L; Ramírez-Flores PN; Silva-Ramírez B; Peñuelas-Urquides K; Cabello-Ruiz ED; Castorena-Torres F; Bermúdez de León M
Int J Mol Sci; 2024 Feb; 25(3):. PubMed ID: 38339037
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
